CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tanvex BioPharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tanvex BioPharma Inc
Floor 4, Willow House, Cricket Square,
P O BOX 2804
GRAND CAYMAN, KY1-1112  Cayman Islands Ticker: 65416541
Business Summary
Tanvex BioPharma, Inc. is a holding company. The Company and its subsidiaries are engaged in the research and development of biosimilar products, biological production processes, and the contract development and manufacturing of biological medicines. It excels in areas such as strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and warehousing, sales, and distribution. Its product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), and Perjeta (TX-52). The Company has two subsidiaries, namely Tanvex Biologies Corporation (Tanvex Taiwan) and Tanvex BioPharma USA, Inc. (Tanvex USA). Tanvex Taiwan is responsible for initial stage cell line development and bioprocess development, while Tanvex USA is responsible for further cell line and process development, scaling up the process to achieve commercialization and mass production.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Lin ChengChen 9/5/2024 5/15/2015
Chief Executive Officer StephenLam 9/5/2024 9/5/2024
Chief Financial Officer, Corporate Governance Officer JunyiLuan 11/11/2024 11/11/2024
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
TANVEX BIOLOGICS CORP 2030 MAIN ST #520 IRVINE CA US
Tanvex BioPharma USA, Inc. 10421 Pacific Center Court San Diego CA United States

Business Names
Business Name
6541
Tanvex BioPharma USA, Inc.

General Information
Outstanding Shares: 164,071,367 (As of 9/30/2024)
Shareholders: 16,097
Stock Exchange: TPE


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024